(2020. május 26.) „A Phase III study to investigate a vaccine against COVID-19”. DOI:10.1186/ISRCTN89951424. ISRCTN89951424.
(2020) „Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects”. Reviews in Medical Virologyn/a (n/a), e2183. o. DOI:10.1002/rmv.2183. PMID33594794.
(2008. február 1.) „SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway”. Cell Research18 (2), 290–301. o. DOI:10.1038/cr.2008.15. PMID18227861.
(2021. január 1.) „Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”. Lancet397 (10269), 99–111. o. DOI:10.1016/S0140-6736(20)32661-1. PMID33306989.
(2021. február 1.) „Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials”. Lancet397 (10277), 881–891. o. DOI:10.1016/S0140-6736(21)00432-3. PMID33617777.
(2021. február 1.) „Covid-19: The E484K mutation and the risks it poses”. BMJ372, n359. o. DOI:10.1136/bmj.n359. PMID33547053.
(2020. december 1.) „Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis”. BMJ371, m4750. o. DOI:10.1136/bmj.m4750. PMID33323376.
(2020) „Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects”. Reviews in Medical Virologyn/a (n/a), e2183. o. DOI:10.1002/rmv.2183. PMID33594794.
(2008. február 1.) „SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway”. Cell Research18 (2), 290–301. o. DOI:10.1038/cr.2008.15. PMID18227861.
(2021. január 1.) „Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK”. Lancet397 (10269), 99–111. o. DOI:10.1016/S0140-6736(20)32661-1. PMID33306989.
(2021. február 1.) „Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials”. Lancet397 (10277), 881–891. o. DOI:10.1016/S0140-6736(21)00432-3. PMID33617777.
(2021. február 1.) „Covid-19: The E484K mutation and the risks it poses”. BMJ372, n359. o. DOI:10.1136/bmj.n359. PMID33547053.
(2020. december 1.) „Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis”. BMJ371, m4750. o. DOI:10.1136/bmj.m4750. PMID33323376.